An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up Academic Article uri icon


MeSH Major

  • Prostate-Specific Antigen
  • Prostatic Neoplasms


  • The current data suggest that interinstitutional and interspecialty comparisons of treatment outcome for patients with prostate carcinoma are possible but that results must be based on all major prognostic variables to be meaningful. Analyzed in this fashion, 5-year PSA results were similar for patients in low-risk and intermediate-risk groups, regardless of the form of therapy. Findings from prospective, randomized trials using survival (cause specific and overall) as the end point for judging treatment efficacy and longer follow-up will be needed to validate these findings and to identify the most appropriate management option for patients with all stages of disease.

publication date

  • November 15, 2002



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.10919

PubMed ID

  • 12412166

Additional Document Info

start page

  • 2126

end page

  • 35


  • 95


  • 10